JAK3 and laryngotracheoesophageal cleft: Another study (42) showed that JAK2 and JAK3 mutations in LC were related to the expression of programmed cell death ligand-1 (PD-L1), and patients with JAK3 gene mutations might benefit from immunotherapy.